#China #Hong Kong #Viva Biotech #AI Drug R&D #CDMO Growth

Viva Biotech's 2026 Interim Results Overview

On August 26, 2026, Viva Biotech Holdings Group, trading under stock code 1873.HK, released its latest interim financial results. The highlights include a revenue of RMB 1,006.5 million, marking a remarkable increase of 21.0% year-over-year and a gross profit of RMB 341.7 million, representing a gross margin of 34.0%. This growth was notably fueled by Langhua Pharmaceutical's Contract Development and Manufacturing Organization (CDMO) business, which has seen substantial operational developments.

Key Financial Insights

The overall financial performance for the first half of 2026 shows another year of progress for the Group despite certain challenges. Even though the net profit stood at RMB 100.9 million with a non-IFRS adjusted profit of RMB 128.3 million, both figures indicate a decline compared to 2025. This downturn was attributed to decreased investment income from strategic partnerships, unfavorable foreign exchange fluctuations, and increased research and development (R&D) expenditures associated with new ventures.

Drug R&D Fueled by AI Innovations

Viva Biotech's Contract Research Organization (CRO) revenue reached RMB 405.1 million, supported by a strong pipeline of projects and the increasing integration of AI technologies into drug discovery processes. The company anticipates maintaining growth rates for the remainder of 2026, bolstered by a burgeoning order backlog and expanding technological capabilities. As of mid-2026, the number of CRO clients surged to 1,984, including collaborations with ten of the world’s leading pharmaceutical firms.

The delivery of over 108,163 protein structures to clients positions Viva Biotech at the forefront of protein structure determination globally. This advancement is strongly linked to the company’s AI-driven initiatives which have facilitated quicker and more effective drug discovery workflows.

Advances in Commercial Manufacturing

The CDMO segment showed robust performance, particularly through Langhua Pharmaceutical, which reported total revenues of RMB 601.4 million — a substantial increase of approximately 47.0% from the prior year. This remarkable growth is primarily due to successful project completions, where a peptide project began commercial stockpiling and a small-molecule project advanced to process performance qualification (PPQ). The total production capacity was reported at 860 cubic meters, sufficient to support anticipated increases in new product production over a two-year horizon.

In response to growth, a new business unit focusing on Peptides, Proteins, and Oligo Nucleotides (PPO) was established, emphasizing the Group’s commitment to advancing its technological capabilities. With a total of 21 peptide projects completed and 19 more in motion, the PPO business unit demonstrates promising potential for future developments.

Strategic Incubation Projects

During the first half of 2026, the Group capitalized on earlier investments, realizing approximately RMB 218.4 million from successful exits of incubated companies. Plans are underway to use these funds for incubating additional projects, utilizing their sophisticated AI-driven platforms.

Over the past year, Viva Biotech has incubated 93 startup companies and is currently developing nearly 232 pipelines, highlighting its extensive investment in innovation and drug development. Many of these projects are entering clinical stages, further reinforcing the company’s strategic position within the biotech industry.

Conclusion

Viva Biotech's 2026 interim results illustrate an organization at the juncture of substantial growth and innovation in the biotech sector. With a significant emphasis on AI’s role in drug discovery and the expansion of its CDMO services, the company is poised to make impactful strides in the coming years. The integration of advanced technologies not only enhances operational efficiency but also improves outcomes in pharmaceutical developments, ensuring that Viva Biotech remains a key player in the global market.

As the company continues to navigate through economic challenges and bolster its R&D efforts, all eyes will be on its ability to maintain this growth momentum and explore new frontiers in drug development.